Office of Research & Development |
![]() ![]() |
Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease. LJ Blair et al.Expert Opinion on Therapeutic Targets, Oct. 2014
Gestures make memories, but what kind? Patients with impaired procedural memory display disruptions in gesture production and comprehension. NB Klooster et al. Frontiers of Human Neuroscience, Jan. 13, 2015
Treating age-related macular degeneration: comparing the use of two drugs among Medicare and Veterans Affairs populations. S Pershing et al. Health Affairs, Feb. 2015
Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling Veterans. DM Richardson, et al. Clinical Infectious Disease, March 31, 2015 (epub ahead of print)
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesencymal to epithelial transition. G Malty et al.Laboratory Investigation, April 13, 2015
Site-level variation in and practice associated with dabigatran adherence.S Shore et al. Journal of the American Medical Association. April 14, 2015
Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JS Kutner et al. JAMA Internal Medicine, May 1, 2015
Isoform-selective genetic inhibition of constitutive cytosolic Hsp70 activity promotes client tau degradation using an altered co-chaperone complement. SN Fontaine et al. The Journal of Biological Chemistry, May 22, 2015
A break-even analysis for dementia care collaboration: partners in dementia care. RO Morgan et al. Journal of General Internal Medicine, June 2015
How does geographic access affect in-hospital mortality for Veterans with acute ischemic stroke? DC Ripley, et al. Medical Care, June 2015